文献速递妇科

卵巢癌PD-L1表达及PARP抑制剂协同抗肿瘤效应

Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
PubMed 文献 · Gynecol Oncol · 2020-01-24

该研究检测卵巢癌组织中PD-L1表达并分析其与预后关系,同时在体外和体内探索PARP抑制剂与PD-L1单抗联合抗肿瘤的效果及机制。结果显示PD-L1高表达与FIGO分期相关且为独立不良预后因素,PARP抑制剂通过Chk1通路上调PD-L1,联合PD-L1阻断具有协同抗肿瘤作用。

要点

  • 卵巢癌组织PD-L1表达与FIGO分期相关(P=0.026)。
  • PD-L1高表达者总生存显著更差(P=0.0005,HR=2.689)。
  • PARP抑制剂经Chk1通路上调PD-L1,联合PD-L1阻断有协同抗肿瘤效应。

核心结论

  • PARP抑制剂通过促进Chk1磷酸化诱导PD-L1表达上调。
  • 拮抗PD-L1可逆转PARP抑制剂对CD8+T细胞的抑制作用,并与PARP抑制剂产生协同抗肿瘤效应。

研究设计与样本

  • 研究采用卵巢癌石蜡包埋组织免疫组化检测PD-L1表达,并用流式细胞术检测TILs中PD-L1表达。
  • 体外实验探讨PARP抑制剂上调PD-L1的机制,体内实验验证联合效应。

主要发现

  • 卵巢癌组织PD-L1表达与FIGO分期相关(P=0.026)。
  • PD-L1高表达组总生存显著低于低表达组(P=0.0005,HR=2.689)。
  • PD-L1高表达(P=0.023,HR=2.275)和FIGO分期(P=0.024,HR=11.229)是影响卵巢癌患者生存预后的独立危险因素。
  • 流式细胞术提示卵巢癌细胞中PD-L1+表达与CD8+T细胞计数呈负相关(P=0.054,r=-0.624)。
  • 体内实验显示联合组肿瘤生长体积和质量显著低于对照组(P<0.05)。

临床怎么用

  • 卵巢癌中PD-L1高表达提示预后不良,可作为预后评估参考指标。
  • PARP抑制剂与PD-L1单抗联合可能增强抗肿瘤效果,尤其需关注PD-L1高表达及CD8+T细胞浸润情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian cancer samples were studied to determine the expression of programmed death ligand-1 (PD-L1) and its relationship with prognosis, and to explore the effect and potential mechanism of a PARP inhibitor combined with PD-L1 monoclonal antibody for the treatment of ovarian cancer. MATERIALS AND METHODS: PD-L1 expression in paraffin-embedded tissues of ovarian cancer was detected by immunohistochemistry (IHC). Flow cytometry was used to detect PD-L1 expression in TILs. Furthermore, we investigated the mechanism of the upregulation of PD-L1 expression by PARP inhibitors in vitro and verified the combined effect in vivo. RESULTS: Our study demonstrated that PD-L1 expression in ovarian cancer tissues was associated with the FIGO stage (P = 0.026). OS was significantly lower in high PD-L1 expression group than in the low expression group (P = 0.0005, HR = 2.689), PD-L1 high expression (P = 0.023, HR = 2.275) and FIGO stage (P = 0.024, HR = 11.229) were independent risk factors affecting the survival and prognosis of ovarian cancer patients. Flow cytometry test suggested that PD-L1+ expression was negatively correlated with CD8+ T cell count in ovarian cancer cells (P = 0.054, r = -0.624). In vitro experiments revealed that PD-L1 expression of ovarian cancer cell lines was upregulated after intervention with PARP inhibitors through the Chk1 pathway. The results of in vivo experiments suggested that the growth volume and quality of tumors in the combination group were significantly lower than those in control group (P < 0.05). CONCLUSIONS: PARP inhibitors could induce upregulation of PD-L1 expression by promoting phosphorylation of chk1. Antagonistic PD-L1 could reverse the inhibitory effect of PARP inhibitors on CD8+T cells, and had synergistic antitumor effect with PARP inhibitors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Xue C, Xu Y, Ye W, et al. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol. 2020. PMID: 31987601. doi:10.1016/j.ygyno.2019.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。